newsfilter
← Latest News
Business Wire·

Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results

ARWR
  • Arrowhead Pharmaceuticals announced its 2026 fiscal year financial results for the period ended September 30, 2026, alongside a conference call scheduled for November 12, 2026, at 4:30 p.m. ET.
  • The company reported a net loss attributable to shareholders of $724.2 million for 2026, compared to a loss of $1.6 million in 2025, driven primarily by a $215 million acquisition cost for a Priority Review Voucher.
  • REDEMPLO (plozasiran) prescriptions for familial chylomicronemia syndrome (FCS) grew 63% quarter-over-quarter, reaching 950 cumulative new-to-brand prescriptions by quarter-end with additional 300 received subsequently.
  • REDEMPLO achieved marketing authorization in Germany, the United Kingdom, 160 million U.S. lives covered in payer formularies, and expanded to over 860 unique prescribing practitioners.
  • The U.S. FDA granted REDEMPLO entry into the Split Real Time Application Review (STAR) pilot program for severe hypertriglyceridemia (sHTG), enabling a potential 6-month priority review with a target to launch in Q2 2027 pending approval.
  • Phase 3 SHASTA-3 and SHASTA-4 clinical trials for plozasiran in sHTG successfully met primary endpoints, showing 79% to 81% median triglyceride reductions from baseline and a 78% reduction in acute pancreatitis events versus placebo.
  • Long-term data from the PALISADE extension demonstrated sustained median triglyceride reductions of 76% over 24 months for patients with FCS.
  • Interim results for ARO-DIMER-PA, a dual-functional RNAi therapeutic for atherosclerotic cardiovascular disease, validated the TRiM platform's ability to silence two genes simultaneously, achieving significant reductions in LDL-C, PCSK9, and triglycerides.
  • Interim results for ARO-MAPT in Alzheimer's disease showed up to an 85% reduction in cerebrospinal fluid total tau, representing the first clinical validation of siRNA delivery across the blood-brain barrier.
  • Enrollment for the Phase 3 YOSEMITE trial of zodasiran in homozygous familial hypercholesterolemia was completed with 70 participants, with results expected in mid-2027.
  • The company refinanced its credit facility, establishing a new $400 million senior secured term loan with an interest rate of SOFR plus 5.50% and a maturity date in November 2031, eliminating previous prepayment sweeps.
  • The Board of Directors approved a change to the fiscal year-end from September 30 to December 31, effective January 1, 2027, requiring a transition report for the three-month period ending December 31, 2026.
  • Total cash resources at September 30, 2026, stood at $1.19 billion, comprising $62.7 million in cash equivalents and $1.13 billion in available-for-sale securities.
  • Arrowhead retained commercial rights to REDEMPLO in all geographies outside of Greater China, where Sanofi holds development and commercialization rights.